Deoxyribonucleic Acid (DNA) Nanotechnology Market Report 2025

The deoxyribonucleic acid (DNA) nanotechnology market size has grown exponentially in recent years. It will grow from $5.55 billion in 2024 to $6.97 billion in 2025 at a compound annual growth rate (CAGR) of 25.7%. The growth in the historic period can be attributed to increasing funding for DNA research, rising adoption of DNA computing technologies, early breakthroughs in DNA origami structures, growing collaboration between academic institutions and industry, and initial successes in molecular-level diagnostics.

The deoxyribonucleic acid (DNA) nanotechnology market size is expected to see exponential growth in the next few years. It will grow to $17.18 billion in 2029 at a compound annual growth rate (CAGR) of 25.3%. The growth in the forecast period can be attributed to the expanding applications of DNA nanostructures in personalized medicine, increasing demand for targeted drug delivery systems, the rise of nanoscale robotic systems based on DNA, growing focus on eco-friendly and sustainable nanomaterials, and the surge in demand for precision diagnostics using DNA platforms. Key trends expected during the forecast period include advancements in DNA self-assembly techniques, continuous innovations in DNA-based biosensors, development of DNA nanorobots for medical applications, increased R\&D in structural DNA nanotechnology, and the integration of DNA systems with quantum computing.

The rising prevalence of genetic diseases is expected to drive the growth of the deoxyribonucleic acid (DNA) nanotechnology market going forward. Genetic diseases are disorders caused by changes or mutations in DNA, which may be inherited or arise spontaneously, impacting health, development, or body function. The increase in genetic diseases is linked to greater awareness and advancements in diagnostic technologies, enabling earlier and more accurate detection of previously undiagnosed conditions. DNA nanotechnology supports the management of genetic diseases by allowing precise targeting of defective genes, facilitating accurate diagnosis and personalized treatments. It improves therapeutic outcomes through controlled drug delivery and gene editing, enhancing patient care and disease management. For instance, in September 2023, according to the Cystic Fibrosis Trust, a UK-based national charity, 11,148 patients were diagnosed with cystic fibrosis in 2022, up from 10,908 in 2021. Therefore, the rising prevalence of genetic diseases is fueling the growth of the DNA nanotechnology market.

Major companies in the DNA nanotechnology market are focusing on developing advanced solutions such as AI-powered DNA sequencing to enhance accuracy and enable precise molecular diagnostics and nanodevice design. AI-based DNA sequencing uses artificial intelligence to rapidly analyze and interpret DNA data, improving speed, accuracy, and personalized disease detection. For instance, in May 2025, the Indian Institute of Technology, an India-based technical institute, introduced quantum AI nanotechnology for rapid, highly accurate, and cost-effective early detection of genetic mutations, including cancer-related mutations. This technology combines explainable AI with quantum transport mechanisms to decode raw electrical signals from DNA sequencing with exceptional precision. Using solid-state nanopore or nanogap devices, it captures unique electronic signatures of nucleotides, enabling comprehensive detection of natural, epigenetic, and artificial DNA mutations, thereby transforming genomics, personalized medicine, and early cancer diagnostics.

In August 2022, SomaLogic Inc., a US-based AI-driven proteomics technology company, acquired Palamedrix Inc. for \$50.9 million. This acquisition allows SomaLogic to advance its next-generation SomaScan proteomic assay by integrating Palamedrix’s DNA nanotechnology, miniaturization, and biosensor expertise, supporting expansion into biopharma, academic research, and precision diagnostics. Palamedrix Inc. is a US-based biotechnology company specializing in DNA nanotechnology.

Major players in the deoxyribonucleic acid (dna) nanotechnology market are Twist Bioscience Corporation, SomaLogic Inc., Alamar Biosciences Inc., Nanion Technologies GmbH, Eligo Bioscience SA, DNA Nanobots LLC, Nanovery Limited, Parabon NanoLabs Inc., tilibit nanosystems GmbH, Luna Nanotech Inc., Code Biotherapeutics Inc., Sona Nanotech Inc., Cello Therapeutics Inc., Esya Labs Inc., NuProbe Global Inc., Ansa Biotechnologies Inc., GATTAquant GmbH, ARIZ Precision Medicine Inc., NanoApps Medical Inc., Aura Biosciences Inc.

North America was the largest region in the deoxyribonucleic acid (DNA) nanotechnology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in deoxyribonucleic acid (DNA) nanotechnology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the deoxyribonucleic acid (DNA) nanotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Deoxyribonucleic acid (DNA) nanotechnology is a field that leverages the molecular structure and base-pairing properties of DNA to design and construct nanoscale structures and devices. It enables the creation of precise, programmable assemblies using DNA strands. The primary objective is to develop novel materials, biosensors, and molecular machines for applications in medicine, diagnostics, and nanofabrication.

The key types of DNA nanotechnology include dynamic DNA nanotechnology and structural DNA nanotechnology. Dynamic DNA nanotechnology allows the creation of programmable systems that respond to molecular signals for applications such as targeted drug delivery, biosensing, and autonomous operations. These systems are available in various formulations, including water-soluble, oil-soluble, and hybrid forms, and are distributed through online sales, direct sales, retail outlets, and distributors or wholesalers. Applications include smart pills, nanolithography, targeted drug delivery, and more, serving end users such as academic and research institutions, biotechnology and pharmaceutical companies, and other related sectors.

The deoxyribonucleic acid (DNA) nanotechnology market research report is one of a series of new reports that provides deoxyribonucleic acid (DNA) nanotechnology market statistics, including the deoxyribonucleic acid (DNA) nanotechnology industry global market size, regional shares, competitors with the deoxyribonucleic acid (DNA) nanotechnology market share, detailed deoxyribonucleic acid (DNA) nanotechnology market segments, market trends, opportunities, and any further data you may need to thrive in the deoxyribonucleic acid (DNA) nanotechnology industry. This deoxyribonucleic acid (DNA) nanotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The deoxyribonucleic acid (DNA) nanotechnology market consists of revenues earned by entities by providing services such as custom deoxyribonucleic acid nanostructure design, deoxyribonucleic acid nanostructure synthesis and fabrication, targeted drug delivery solutions using deoxyribonucleic acid nanostructures, and research and development contract services. The market value includes the value of related goods sold by the service provider or included within the service offering. The deoxyribonucleic acid (DNA) nanotechnology market also includes of sales of DNA nanorobots, DNA scaffolds for nanofabrication, DNA computing systems and DNA origami structures. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.